Compare Citius Pharmaceuticals Inc (CTXR) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Alliant Energy Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Alliant Energy Corporation trades at $65.85 (market cap $16.99B). The key difference: Alliant Energy Corporation is far larger — about 1247.4× Citius Pharmaceuticals Inc's market cap, and Alliant Energy Corporation pays a 3.27% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Alliant Energy Corporation for 64 Days on average.
| CTXR | LNT | |
|---|---|---|
Market Cap | $13.62M | $16.99B |
Volume | 132,438 | 2,488,387 |
Sector | Health | Utilities |
52-Week High | $1.82 | $78.03 |
52-Week Low | $0.48 | $63.21 |
Typical Hold Time | 17 Days | 64 Days |
Enterprise Value | $3.79M | $29.08B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Alliant Energy (LNT) trades at $65.50, up 0.44% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with Q2 2026 EPS beating expectations at $0.65 and consistent revenue growth to $4.36B in 2025. Analyst consensus is positive with a $77.00 price target and 52% buy ratings. Recent institutional activity includes significant purchases by California State Teachers Retirement System and Nykredit A/S.
LNT presents a compelling investment case with stable utility operations, 23-year dividend growth, and a $13.4B capital investment plan supporting 5-7% earnings growth. Key risks include rising debt levels (debt-to-asset ratio increased to 48.48% in 2025) and sensitivity to interest rate changes. The stock offers defensive value with current momentum favoring upside toward analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
